Cubist’s Cubicin gets boost from expanded indication

Share this article:
The FDA has approved broader use for Cubist Pharmaceuticals’ Cubicin intravenous antibiotic to also treat bloodstream infections, including a form of endocarditis. Cubist plans to market Cubicin for the new indication immediately, the Lexington, MA-firm said. Cubicin was originally approved in late 2003, for the treatment of complicated skin and skin structure infection and has reached $100 million in sales since then. In November 2005, the company announced it would boost the size of its hospital sales force from 99 to 135 in anticipation of today’s regulatory approval.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.